Treating coronavirus infection with azithromycin doesn’t seem to make sense, new research says.
The antibiotic azithromycin, which is prescribed to patients with coronavirus, does not improve their condition. When treating COVID-19, it is better to completely abandon this drug until the bacteria become addicted to it.
Earlier, virologists from France stated that azithromycin helps in the treatment of coronavirus, and the combination of azithromycin and the antimalarial agent hydroxychloroquine significantly reduces the severity of COVID-19.
- Brief Anger Hampers Blood Vessel Function Leading to Increased Risk of Heart Disease and Stroke – New Study
- New Blood Test Pinpoints Future Stroke Risk – Study Identifies Inflammatory Molecules as Key Biomarker
- Enceladus: A Potential Haven for Extraterrestrial Life in its Hidden Ocean Depths
- New Experiment: Dark Matter Is Not As ‘DARK’ As All We Think
- Scientists in Fear of This New Predator From Red Sea Eating Native Species in Mediterranean
Scientists from the University of California at San Francisco with scientists from Stanford University conducted a study and found that the use of azithromycin by COVID patients did not reduce their risk of entering intensive care or death from infection.
“It is important that doctors around the world in the near future stop using this drug to fight COVID-19, which will reduce the risk that bacteria will begin to acquire resistance to its action,” American and British experts say.
They conducted a study involving 298 people who were diagnosed with the coronavirus.
Patients with mild to moderate forms of the disease taking high doses of azithromycin did not improve their condition.
In severely ill patients, the antibiotic did not reduce their likelihood of being admitted to intensive care.
These findings do not support the routine use of azithromycin for outpatient SARS-CoV-2 infection
the scientists concluded.
Most of the trials done so far with azithromycin have focused on hospitalized patients with pretty severe disease.
Our paper is one of the first placebo-controlled studies showing no role for azithromycin in outpatients.
Photo by Dimitar DILKOFF / AFP) (Photo by DIMITAR DILKOFF/AFP via Getty Images